By targeting these receptors directly, Tanaka and colleagues hoped to shut down lupus pathology at the earliest point in the process, preventing interferon release and the subsequent autoimmune ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...

By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal ...

in collaboration with Nizam’s Institute of Medical Sciences (NIMS), Hyderabad has unveiled publicly available datasets comprising digitized histopathological images of brain cancer and kidney disease ...